SCHEMBL12430951

SCHEMBL12430951

Cc1cc(Nc2cc(C)[nH]n2)nc(Nc2ccccc2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.63
GSK3B P49841 2/20 0.63
SRC P12931 1/20 0.63
PAK4 O96013 2/20 0.59
PLK4 O00444 1/20 0.59
IGF1R P08069 8/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
MAPT P10636 2/20 0.57
HTT P42858 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
GPR55 Q9Y2T6 1/20 0.57
TAAR1 Q96RJ0 1/20 0.54
AURKB Q96GD4 3/20 0.51
DAPK3 O43293 1/20 0.51
JAK2 O60674 1/20 0.51
ABL1 P00519 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
CSF1R P07333 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12510417 0.89 IGF1R (0.55) AURKAGSK3BSRCIGF1RKDM4E
SCHEMBL12430944 0.86 AURKA (0.65) AURKAIGF1RKDM4ELMNAMAPT
SCHEMBL12430924 0.85 AURKA (0.59) AURKAGSK3BSRCPAK4PLK4
SCHEMBL12340074 0.83 MAPT (0.71) IGF1RKDM4ELMNAMAPTHTT
SCHEMBL9820151 0.82 MEN1 (0.65) AURKAGSK3BSRCPAK4PLK4
SCHEMBL12430950 0.81 AURKA (0.55) AURKAGSK3BSRCPAK4PLK4
SCHEMBL2206402 0.81 MAPT (0.57) IGF1RKDM4ELMNAMAPTHTT
SCHEMBL12510416 0.80 KDM4E (0.56) IGF1RKDM4ELMNAMAPTHTT
SCHEMBL802286 0.79 ITK (0.69) AURKAGSK3BSRCIGF1RAURKB
SCHEMBL12430947 0.78 AURKA (0.71) AURKAGSK3BSRCPAK4PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKA 3/4885GSK3B 1/4885SRC 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.